Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Supported by Merck Sharp and Dohme, a subsidiary of Merck (Rahway, NJ). Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the patients ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

Shares of Sun Pharmaceutical Industries extended ... Sun Pharma has acquired the rights from Merck, Sharp & Dohme (MSD) to develop, manufacture, and commercialise Tedizolid Phosphate in India.

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) with partial responses in ...

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising ...